In this paper I will consider the relationship between research in contemporary genetic therapy and the biblical and theological understanding of the redemptive work of Christ in his atoning work on the cross. Historic Christianity has understood that both physical and human creation was initially “good,” but that disease and death came as a result of the Fall and the curse of sin. The crucial question is: when Christ died for sin on the cross, did his death cover all aspects of the curse and beyond the remittance of forensic guilt that all believers assume is theirs when they embrace Christ’s finished work? In other words, is there more to Christ’s “already” work of redemption? We know there is the “not yet” of Christ’s redemptive work in the completed redemption in our new resurrection bodies.Modern Western medicine has generally been understood to be rooted within the parameters of the basic Christian creational and redemptive worldview. However, the Human Genome Project achievements have raised the challenging scientific questions of not only how such forms of medicine will be done, but, for the Christian, whether such a singularly unique form of medicine could be called “redemptive therapy?” In conjunction there are the equally, and probably more far reaching questions about the ethical, theological, and practical implications of such for both the church and society. My paper will be, of necessity, explorative and suggestive. Given our time constraints, my presentation will be in four parts: 1) A brief historical background of the nature and present status of genetic therapy 2) A brief review of the biblically pertinent and theologically relevant materials3) A summary analysis of the bioethical implications for the church and society4) A time for Q&A. There will be a print handout which includes a brief select bibliography for further study.